A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

Background The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. Case presentation We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic senso...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal for immunotherapy of cancer Ročník 6; číslo 1; s. 110 - 6
Hlavní autoři:	Ghosn, Jaqueline, Vicino, Alex, Michielin, Olivier, Coukos, George, Kuntzer, Thierry, Obeid, Michel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 22.10.2018 BMJ Publishing Group LTD BMJ Publishing Group
Témata:	Antibodies Biopsy Case Report Case Reports Checkpoint inhibitors Exocrine glands Hemoglobin Hepatitis Immune-related adverse events Immunology Immunotherapy Life Sciences Medicine Medicine & Public Health Melanoma Metastasis Monoclonal antibodies Neuro-Sjögren’s syndrome Oncology PD-1 Pembrolizumab Remission (Medicine) Targeted cancer therapy Viruses Checkpoint inhibitors Pembrolizumab Immune-related adverse events Neuro-Sjögren’s syndrome PD-1
ISSN:	2051-1426, 2051-1426
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!